Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan
03 Junio 2020 - 11:00AM
Sanofi to launch “Action 2020”, a worldwide employee stock purchase
plan
Sanofi to launch “Action 2020”, a worldwide employee
stock purchase plan
- A plan taking place in almost 75 countries
- Subscription per five shares entitle the employee to one
matching share1
PARIS – June 3, 2020 – Sanofi
announces the launch of “Action 2020” on June 8, 2020, a worldwide
stock purchase plan reserved for its employees, which should take
place in almost 75 countries. Sanofi’s strategy aims at providing
long-term growth and value for its stakeholders while turning
innovation into transformative medicines for patients. By doing
such a capital increase, Sanofi intends to better associate its
employees who are key contributors in this value creation, to the
future development and results of the company.
On February 5, 2020 the Board of Directors
authorized an issuance of ordinary shares of Sanofi for the benefit
of employees participating in the Group Savings Plan. The
subscription price is €70.67. It is equal to 80 % of the average of
the opening price of the Sanofi share on Euronext Paris over the 20
stock exchange trading sessions preceding June 2, 2020. Any
subscription per five shares as part of such issuance shall entitle
the employee to one matching share. Subscriptions equal to or
higher than 20 shares shall give right to 4 matching shares as an
employer contribution. Employees may choose to subscribe a maximum
of 1,500 shares within the limit of a maximum subscription amount
which does not exceed 25% of their gross annual remuneration.
An eligibility condition of three months of
seniority as at the closing date of the subscription period will be
applied. The subscription period will run from June 8, 2020
(inclusive) until June 26, 2020 (inclusive).
The issuance of new shares and the share
delivery process should occur at the end of July 2020.
The total number of Sanofi shares that may be
issued under the plan is limited to 6,269,231 shares (corresponding
to a share capital increase in terms of par value of up to
€12,538,461, representing 0.5 % of the share capital).
The newly issued shares, including the matching
shares (the “Shares”) will be subscribed (or delivered) either
directly or through employee shareholding funds (“FCPE”), depending
on the legal and/or tax regulations applicable in the various
countries of residence of the beneficiaries of the capital
increase.
The Shares will be fully fungible with the
existing ordinary shares of Sanofi and will be entitled to
dividends distributed on benefits relating to the fiscal year
starting as of January 1, 2020.
The voting rights attached to the Shares
subscribed will be directly exercised by the employees.
The subscribers to the plan will be required to
hold the Shares or the corresponding “FCPE” units during a period
of approximately five years, i.e. until May 31, 2025, except upon
the occurrence of an early exit event provided in Article R.
3324-22 of the French Labor Code and authorized in the country of
the subscriber.
The listing of the Shares on the Euronext Paris
market (ISIN Code: FR0000120578) on the same listing line as the
existing shares will be requested as soon as possible after the
completion of the capital increase.
This press release does not constitute an offer
to sell or a solicitation to purchase Sanofi shares. The offering
of Sanofi shares reserved for employees will be conducted only in
countries where such an offering has been registered or notified to
the competent local authorities and/or following approval of a
prospectus by the competent local authorities or in consideration
of an exemption to prepare a prospectus or to make any registration
or notification of the offering, when such a procedure is
required.
More generally, the offering will only be
conducted in countries where all required filing procedures and/or
notifications have been completed and the authorizations have been
obtained, and procedures for consultation or information of staff
representatives have been fulfilled.
This press release is not intended for, and
copies thereof should not be sent to, countries in which such a
prospectus has been approved or such an exemption is not available
or where all of the required filing procedures, notifications,
consultation and/or information required have been completed or
where the authorizations have been obtained. This applies in
particular to Cameroon and Morocco, where the formalities are still
pending with the authorities, but could also involve other
countries.
For any questions related to the following share
capital increase, each beneficiary may consult the information
booklet and all other documents made available and/or contact
his/her human resources manager.
This press release is made in reliance of the
exemption from publishing a prospectus provided for in Article 1
4°i) and 5°h) of the Prospectus Regulation (EU) 2017/1129 . It
constitutes the document required to qualify for the exemption from
the requirement to publish a prospectus as defined in the EU
Prospectus Regulation
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Media Relations Contact Nicolas Kressmann Tel.:
+33 (0)1 53 77 46 46 mr@sanofi.com |
Investor
Relations Contact Felix Lauscher Tel.: +33 (0)1 53 77 45
45 ir@sanofi.com |
|
. We stand by the few who suffer from rare
1 Subscriptions equal to or higher than 20 shares shall give
right to 4 matching shares as an employer contribution
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024